Tecan and Covaris co-market Freedom EVO® with Adaptive Focused Acoustics™
News Nov 19, 2010
Tecan is collaborating with Covaris, Inc., to co-promote the Freedom EVO® liquid handling platform with integrated Adaptive Focused Acoustics™ (AFA). This co-marketing agreement will allow customers to benefit from both the advanced capabilities of Tecan’s Freedom EVO systems and Covaris’ controlled non-contact acoustic sample preparation technology.
Covaris’ AFA systems have already been successfully integrated into the Freedom EVO platform for several applications, and this joint offering will now be available to customers worldwide for sample preparation, compound management and next generation sequencing applications.
Kevin Moore, Tecan’s Director of Market and Application Management for BioPharma, said: “AFA is gaining widespread acceptance in the compound management community for rapid thawing, mixing and dissolution of samples, as well as for DNA shearing in the exciting area of next generation sequencing. We are extremely pleased to be working together with Covaris to provide valuable automated solutions to our customers working in these areas.”
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018